Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 6/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.51 |
| ▸ | JAK3 | P52333 | 6/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103235 | 0.92 | JAK2 (0.58) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL5094669 | 0.89 | ACVR1 (0.57) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL5097014 | 0.89 | FLT3 (0.49) | ACVR1JAK2JAK3AIMP2PTK2 | |
| SCHEMBL5103237 | 0.89 | JAK2 (0.50) | ACVR1JAK2JAK3ABL1BCR | |
| SCHEMBL4763658 | 0.88 | JAK2 (0.51) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL5094766 | 0.87 | JAK2 (0.51) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL5090937 | 0.87 | ACVR1 (0.57) | ACVR1JAK2JAK3PLK4 | |
| SCHEMBL4629751 | 0.86 | ACVR1 (0.49) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL3271487 | 0.85 | JAK2 (0.61) | ACVR1JAK2JAK3PLK4ABL1 | |
| SCHEMBL4629323 | 0.81 | JAK2 (0.57) | ACVR1JAK2JAK3ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | ACVR1 1609/4885JAK2 205/4885JAK3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.